Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody–drug conjugates and bispecific antibodies
出版年份 2021 全文链接
标题
Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody–drug conjugates and bispecific antibodies
作者
关键词
-
出版物
BREAST CANCER RESEARCH AND TREATMENT
Volume 191, Issue 2, Pages 291-302
出版商
Springer Science and Business Media LLC
发表日期
2021-10-30
DOI
10.1007/s10549-021-06423-0
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Tumor immunological phenotype signature-based high-throughput screening for the discovery of combination immunotherapy compounds
- (2021) Haiyan Wang et al. Science Advances
- Clinical Development of New Antibody–Drug Conjugates in Breast Cancer: To Infinity and Beyond
- (2021) Romualdo Barroso-Sousa et al. BIODRUGS
- LBA16 KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC
- (2021) J. Cortés et al. ANNALS OF ONCOLOGY
- Nanoparticle delivery of immunostimulatory oligonucleotides enhances response to checkpoint inhibitor therapeutics
- (2020) Colin G. Buss et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer
- (2020) Juniper A Scribner et al. MOLECULAR CANCER THERAPEUTICS
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
- (2020) Javier Cortes et al. LANCET
- Emerging nanomedicines for effective breast cancer immunotherapy
- (2020) Amirhossein Bahreyni et al. JOURNAL OF NANOBIOTECHNOLOGY
- Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies
- (2020) Julius Strauss et al. Journal for ImmunoTherapy of Cancer
- PDL-1 Antibody Drug Conjugate for Selective Chemo-Guided Immune Modulation of Cancer
- (2019) Samaresh Sau et al. Cancers
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
- (2019) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bispecific antibodies: a mechanistic review of the pipeline
- (2019) Aran F. Labrijn et al. NATURE REVIEWS DRUG DISCOVERY
- A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer
- (2019) Joanie Del Bano et al. Frontiers in Immunology
- The emerging role of epigenetic therapeutics in immuno-oncology
- (2019) Michael J. Topper et al. Nature Reviews Clinical Oncology
- Pharmacological modulation of nucleic acid sensors — therapeutic potential and persisting obstacles
- (2019) Claire Vanpouille-Box et al. NATURE REVIEWS DRUG DISCOVERY
- Blockade of ErbB2 and PD-L1 using a bispecific antibody to improve targeted anti-ErbB2 therapy
- (2019) Deepak Mittal et al. OncoImmunology
- Histone deacetylase inhibition promotes intratumoral CD8+ T-cell responses, sensitizing murine breast tumors to anti-PD1
- (2019) Tyler R. McCaw et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology
- (2019) Karen A. Autio et al. CLINICAL CANCER RESEARCH
- Dual inhibition of CSF1R and MAPK pathways using supramolecular nanoparticles enhances macrophage immunotherapy
- (2019) Anujan Ramesh et al. BIOMATERIALS
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Catumaxomab with Activated T-cells Efficiently Lyses Chemoresistant EpCAM-positive Triple-negative Breast Cancer Cell Lines
- (2018) MAKOTO KUBO et al. ANTICANCER RESEARCH
- Mechanisms of resistance to immune checkpoint inhibitors
- (2018) Russell W Jenkins et al. BRITISH JOURNAL OF CANCER
- Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
- (2018) Julius Strauss et al. CLINICAL CANCER RESEARCH
- A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer
- (2018) Cesar August Santa-Maria et al. Oncotarget
- Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages
- (2018) Shicheng Su et al. CELL
- p95HER2–T cell bispecific antibody for breast cancer treatment
- (2018) Irene Rius Ruiz et al. Science Translational Medicine
- Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs
- (2018) Brian J. Christmas et al. Cancer Immunology Research
- Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
- (2017) Leisha A. Emens et al. EUROPEAN JOURNAL OF CANCER
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
- (2017) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Innate immune signaling and regulation in cancer immunotherapy
- (2016) Leticia Corrales et al. CELL RESEARCH
- Generation and characterization of a bispecific diabody targeting both EPH receptor A10 and CD3
- (2015) Haruhiko Kamada et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy
- (2015) A. Yonezawa et al. CLINICAL CANCER RESEARCH
- FDA Approval: Blinatumomab
- (2015) D. Przepiorka et al. CLINICAL CANCER RESEARCH
- Clinical relevance of host immunity in breast cancer: from TILs to the clinic
- (2015) Peter Savas et al. Nature Reviews Clinical Oncology
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab emtansine (T-DM1) renders HER2 + breast cancer highly susceptible to CTLA-4/PD-1 blockade
- (2015) Philipp Müller et al. Science Translational Medicine
- Nanoparticle-Based Immunotherapy for Cancer
- (2014) Kun Shao et al. ACS Nano
- Probody therapeutics for targeting antibodies to diseased tissue
- (2014) Krishna R Polu et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Myeloid-derived suppressor cells in breast cancer
- (2013) Joseph Markowitz et al. BREAST CANCER RESEARCH AND TREATMENT
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index
- (2013) L. R. Desnoyers et al. Science Translational Medicine
- Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer
- (2012) Holbrook E. Kohrt et al. JOURNAL OF CLINICAL INVESTIGATION
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
- (2011) J. Stagg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation